Clinical Research Directory
Browse clinical research sites, groups, and studies.
Alternating Triamcinolone and Platelet-Rich Plasma Therapy for Oral Submucous Fibrosis
Sponsor: Karachi Medical and Dental College
Summary
Oral Submucous Fibrosis (OSF) is a chronic, progressive, potentially malignant disorder characterized by mucosal stiffness, trismus, and burning sensation. This interventional clinical trial evaluates the therapeutic effectiveness of alternating weekly intralesional Triamcinolone Acetonide (TA) and Platelet-Rich Plasma (PRP) injections compared to standard Triamcinolone therapy alone. The purpose is to determine whether sequential anti-inflammatory (TA) and regenerative (PRP) stimulation can produce superior clinical improvement in mouth opening, burning sensation, and mucosal flexibility compared to corticosteroid therapy alone.
Official title: Clinical Efficacy of Alternating Intralesional Triamcinolone Acetonide and Platelet-Rich Plasma Compared to Triamcinolone Alone in Patients With Oral Submucous Fibrosis: A Two-Arm Interventional Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-03
Completion Date
2026-09
Last Updated
2025-12-11
Healthy Volunteers
No
Conditions
Interventions
Platelet-Rich Plasma (PRP) Injections
Autologous Platelet-rich plasma (PRP) injected intralesionally at standard volume for Oral submucous fibrosis (OSF) treatment, administered every alternate week.
Triamcinolone Acetonide
Triamcinolone acetonide 10 mg/mL administered intralesionally once weekly.
Locations (1)
Abbasi Shaheed Hospital
Karachi, Sindh, Pakistan